Orphazyme's creditors to vote on sales agreement at end of May
Sunday’s sales agreement between US-based Kempharm and Orphazyme will be decided on May 30, when the company’s creditors meet to vote on the proposal.
.jpg)
by christopher due karlsson, translated by daniel pedersen
Embattled biotech firm Orphazyme finally has a restructuring proposal after Sunday’s announcement that Kempharm, which is based in the US, has agreed to buy the firm’s assets and activities.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
Orphazyme sells entire business to US biotech company
For subscribers
